Vergleich

Doxycycline (hydrochloride) Europäischer Partner

ArtNr HY-N0565A-10mM
Hersteller MedChem Express
CAS-Nr. 10592-13-9
Menge 10 mM/1 mL
Quantity options 100 mg 10 mM/1 mL 1 ea 1 g 25 mg 500 mg 50 mg 5 g
Kategorie
Typ Inhibitors
Specific against other
Purity 99.99
Citations [1]Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.|[2]Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51.|[3]Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504.|[4]Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561.|[5]Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.|[6]Niv Y. Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis. Digestion. 2016;93(2):167-73.|[7]Manfredsson FP, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther. 2009 Nov;17(11):1857-67.|[8]Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10933-8.
Cancer Lett. 2016 Jun 28;376(1):188-96.|Cell Death Differ. 2019 Nov;26(11):2400-2415. |Cell Rep. 2024 Aug 22;43(9):114662.|Cell. 2023 Feb 2;186(3):591-606.e23.|Nat Cell Biol. 2025 Mar 3.|Sci Adv. 2024 Apr 17;10(16):eadi1782|ACS Infect Dis. 2024 Apr 12;10(4):1327-1338.|Acta Pharmacol Sin. 2024 Aug 26.|Adv Sci (Weinh). 2021 Mar 15;8(10):2004344.|Adv Sci (Weinh). 2025 Jan 21:e2407942.|AMB Express. 2024 Dec 24;14(1):141.|Ann Lab Med. 2021 May 1;41(3):293-301.|Biochem Biophys Res Commun. 30 July 2022.|Biol Res. 2024 Nov 24;57(1):90.|Biomed Pharmacother. 2023 Jun 8;164:114998.|bioRxiv. 2023 Jun 14.|bioRxiv. 2023 Mar 31.|bioRxiv. 2024 July 05.|Cancer Biol Ther. 2022 Dec 31;23(1):328-335.|Cancer Commun (Lond). 2025 Feb 17.|Cancer Res. 2023 Jul 18;CAN-23-0015.|Cancer Res. 2025 Feb 1;85(3):585-601.|Cell Commun Signal. 2022 Apr 12;20(1):52.|Cell Death Differ. 2023 Jun 15.|Cell Death Dis. 2020 May 7;11(5):331.|Cell Death Dis. 2022 Feb 10;13(2):138.|Cell Death Dis. 2025 Mar 12;16(1):170.|Cell Mol Life Sci. 2024 Nov 16;81(1):456.|Cell Prolif. 2023 Aug 17;e13534.|Cell Rep. 2024 Jul 3;43(7):114431.|Clin Exp Pharmacol Physiol. 2023 Apr 22.|Drug Resist Updat. 2024 Jun 24:76:101112.|Emerg Microbes Infect. 2024 Dec;13(1):2321981.|FASEB J. 2020 Dec;34(12):16716-16735.|FASEB J. 2024 Apr 30;38(8):e23628.|Front Cell Infect Microbiol. 28 April 2021.|Heliyon. 2024 May 30.|Inflammopharmacology. 2025 Jan 17.|Int Immunopharmacol. 2024 Jun 24:138:112518.|Int J Mol Med. 2020 Apr;45(4):1187-1194.|Int J Mol Sci. 2025 Mar 18;26(6):2712.|iScience. 2023 Mar.|J Cell Mol Med. 2024 Sep;28(17):e70053.|J Clin Invest. 2024 Jan 18:e171995.|J Med Virol. 2024 May;96(5):e29634.|J Transl Med. 2024 Oct 10;22(1):923.|J Virol. 2024 Aug 30:e0133524.|Katedra farmakologie a toxikologie. 2020 Jul.|Mol Cancer. 2020 Mar 30;19(1):68.|Mol Oncol. 2024 May 22.|Molecules. 2023 Jul 26, 28(15), 5668.|Nat Commun. 2024 Apr 6;15(1):2989.|Nat Genet. 2024 Feb;56(2):294-305.|Nat Microbiol. 2023 Mar;8(3):410-423.|NPJ Parkinsons Dis. 2022 Aug 6;8(1):100.|Oncogene. 2023 Dec 15.|Oncogene. 2024 Oct 23.|Phytomedicine. 2024 Aug 22:134:155958.|Redox Biol. 2023 Mar 21;62:102686.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2023 Jul 11.|Research Square Preprint. 2024 Apr 8.|Research Square Preprint. 2024 Jan 23.|Sci Adv. 2022 Jan 28;8(4):eabl5220.|Sci Adv. 2025 Jan 31;11(5):eadr8837.|Stem Cell Res Ther. 2024 Oct 8;15(1):350.|Theranostics. 2022 Mar 28;12(7):3131-3149.|Vet Microbiol. 2024 May, 292, 110046.|Virol Sin. 2022 May 12;S1995-820X(22)00081-5.|Water Res. 2023 May 21, 120110.|Adv Sci (Weinh). 2022 Jun 2;e2104823.|Adv Sci (Weinh). 2024 Oct 8:e2404756.|Biochem Biophys Res Commun. 6 August 2022.|bioRxiv. 2019 Apr.|bioRxiv. 2024 Jan 23.|bioRxiv. 2025 January 15.|Cancer Commun (Lond). 2023 Dec 28.|Cancer Res Commun. 2024 Jul 1.|Cell Death Dis. 2017 Mar 23;8(3):e2702.|Cell Death Dis. 2021 Apr 20;12(5):413.|Cell Discov. 2024 Nov 5;10(1):112.|Cell Rep. 2021 Jun 8;35(10):109225.|Cell Rep. 2021 Sep 21;36(12):109739.|Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8.|Elife. 2021 Oct 27;10:e65759.|Food Funct. 16th November 2021.|Institute of Pharmacology and Toxicology University of Zürich. 2019 Nov.|J Biol Chem. 2022 Aug 12;102374.|J Biol Chem. 2023 Mar 17;104621.|J Genet Genomics. 2020 Nov 20;47(11):705-712.|Mol Cancer. 2020 Sep 9;19(1):139.|Nat Commun. 2023 Dec 20;14(1):8461.|Nucleic Acids Res. 2024 Aug 21:gkae707.|Patent. US11576860B2.|Patent. US20190365645A1.|Patent. US20190366064A1.|Patent. US 2019/0365645 A1.|Research Square Preprint. 2024 Dec 04.|Research Square Print. 2022 May.|Research Square Print. 2023 Mar 1.|STAR Protoc. 2021 Nov 5;2(4):100881.|STAR Protoc. 2021, 100548.|STAR Protoc. 2022 Apr 13;3(2):101296.|STAR Protoc. 2023 Feb 3;4(1):102092.|Theranostics. 2022 Jan 1;12(3):1187-1203.
Smiles O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])[C@@H](O)[C@]3([H])[C@@H](C)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Antibiotic; Bacterial; MMP; Parasite
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
480.90
Product Description
Doxycycline hydrochloride, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. Doxycycline hydrochloride shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hydrochloride can be used to construct gene expression regulation models[1][2][3][4][5].
Manufacturer - Research Area
Cancer; Infection
Solubility
DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway
Anti-infection; Metabolic Enzyme/Protease
Isoform
Tetracycline
Clinical information
Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 10 mM/1 mL
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen